SEP 18, 2020 6:55 AM PDT

Itraconazole: the key is in the dosage

Precision medicine specific to a patient’s genetics or immune system is spearheading new paths of cancer treatment. Now research from UT Southwestern scientists suggests that precise dosage is just as important in patient care. Looking specifically as a drug called itraconazole which is used to manage infections as well as treat cancer, the research team found that cancer patients required a wide range of dosages for the drug to be effective.

To fight fungal infections, itraconazole, also known as Sporonox, Sporaz, or Orungal, is usually administered at a single, fixed dose independent of the patient. The drug was discovered to be effective in treating several types of cancer (lung, prostate, and skin cancers) over a decade ago by inhibiting cellular growth pathways and stopping the formation of new blood vessels initiated by cancers. Yet the researchers behind this study, which was published recently in the journal Clinical Cancer Research, say that even with a set dosage, lung cancer patients absorb different levels of the drug into their bloodstream.

"What this means going forward is that, in future studies of itraconazole for the treatment of cancer, it may be important to check each patient's drug level and tailor the dose," says first author David Gerber, M.D., a professor of internal medicine and population and data sciences at UTSW. "In this context, there's no one-size-fits-all dose," notes Gerber.

The team tested different regimens of the drug on 13 patients with non-small cell lung cancer who were already scheduled for surgery to remove their tumors. Patients were administered 300 milligrams twice a day with food leading up to their surgeries. When the researchers looked at their tumor samples following surgery, they found that levels of itraconazole varied from 1,244 ng/g to 7,094 ng/g – or an almost sixfold range. Such a large range can’t be explained by body mass and kidney or liver function, say the researchers.

Photo: Pexels

"There was growing evidence that itraconazole conveyed a survival advantage to patients," says Kim. "But, in this new work, we wanted to take a step back and look more at the biology and pharmacology of what was going on with this drug in cancer patients."

"This study highlights the need when repurposing drugs, to look closely at the dosing," says William Trey Putnam, Ph.D., director of the Clinical Pharmacology Center at Texas Tech University Health Sciences Center. "In different diseases, the dosing can end up needing to be quite different."

While the researchers recognize the need for larger studies, they say their findings are statistically significant and call on the need for an improved understanding of itraconazole in cancer treatment. Given the benefits that the drug can have on reducing tumor growth and the inexpensiveness of it, the team says itraconazole merits further investigation.  

Sources: Clinical Cancer Research, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
AUG 12, 2020
Cancer
Comparing Nivolumab and Pembrolizumab in the Treatment of Lung Cancer
AUG 12, 2020
Comparing Nivolumab and Pembrolizumab in the Treatment of Lung Cancer
Since the 1940s, chemotherapy has been a primary treatment option for cancer. The late 20th century brought a new type o ...
SEP 16, 2020
Cancer
I'm addicted to the sun, are you?
SEP 16, 2020
I'm addicted to the sun, are you?
New research published in the Journal of Investigative Dermatology reports evidence that some people are geneticall ...
SEP 22, 2020
Cardiology
Investigating the Mechanism Behind 5-Fluorouracil's Cardiotoxicity
SEP 22, 2020
Investigating the Mechanism Behind 5-Fluorouracil's Cardiotoxicity
Cancer therapies have come quite far, with several options available for many cancers. An issue that has plagued many of ...
SEP 25, 2020
Clinical & Molecular DX
Ray of Hope: Rare Cancer Biomarker Discovered
SEP 25, 2020
Ray of Hope: Rare Cancer Biomarker Discovered
Biliary tract cancer, or BTC, isn’t as talked about as breast or prostate cancers, probably because its incidence ...
SEP 30, 2020
Cancer
How to avoid endocrine disrupting chemicals in your life
SEP 30, 2020
How to avoid endocrine disrupting chemicals in your life
While few people actually enjoy reading product labels and ingredients, a new study from Silent Spring Institute suggest ...
OCT 18, 2020
Cancer
Virus-mimicking drug attacks melanoma tumors
OCT 18, 2020
Virus-mimicking drug attacks melanoma tumors
Research published recently in the journal Science Translational Medicine from scientists at the UCLA Jonsson Compr ...
Loading Comments...